Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
NCT04607954
Recruiting
This phase II trial studies the effects of durvalumab and lurbinectedin in treating patients with extensive stage small cell lung cancer that has come back (relapsed) or has not responded to previous treatment with chemotherapy and immunotherapy (refractory). Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread. Lurbinectedin is in a class of medications called alkylating agents. It works by slowing or stopping the growth of cancer cells in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Refractory Extensive Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma
Register for Updates
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
NCT05168930
Recruiting
This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: New England Cancer Specialists, Scarborough, Maine +3 locations
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Register for Updates
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05520099
Recruiting
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Salinas Valley Memorial Healthcare System, Salinas, California +10 locations
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Colorectal Cancer, Cutaneous Melanoma, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Register for Updates
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295
Recruiting
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Banner Gateway Medical Center, Gilbert, Arizona +316 locations
Conditions: Urothelial Carcinoma
Register for Updates
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
NCT06158828
Recruiting
This phase I/II pilot study aims to enhance the effectiveness of stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). Patients will undergo a stem cell transplant from a half-matched family donor. One week later, patients will receive an additional infusion of immune cells and a drug called interleukin-2. To mitigate the potential complications associated with graft-versus-host-disease, the donated stem cell product undergoes a process that removes a s... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/19/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia
Register for Updates
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417
Recruiting
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/19/2025
Locations: University of California-Irvine, Orange, California +66 locations
Conditions: Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP)
Register for Updates
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
NCT06540963
Recruiting
The purpose of this study is to evaluate the investigational drug, tipifarnib (a pill taken by mouth), in combination with the Food and Drug Administration (FDA) approved drug, naxitimab, administered intravenously (IV; a liquid that continuously goes into your body through a tube that has been placed during a surgery into one of your veins). Naxitamab is FDA approved for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
05/19/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas +2 locations
Conditions: Neuroblastoma Recurrent
Register for Updates
Rehabilitation Outcomes Study
NCT06674889
Recruiting
This pilot health services interventional study aims to prospectively assess the effectiveness of a pre-treatment rehabilitation (prehabilitation) program across a diverse cohort of adult cancer patients via a randomized pilot trial. Upon screening and identification of high-risk features through a central navigation process, patients referred to oncology clinics will be approached to participate in tailored prehabilitation interventions. The study will track and analyze functional outcomes and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: The N.C. Cancer Hospital, Chapel Hill, North Carolina
Conditions: Cancer, Malignant Tumor
Register for Updates
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
NCT06826612
Recruiting
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
05/19/2025
Locations: University of Cincinnati/Cincinnati Children's Hospital, Cincinnati, Ohio +1 locations
Conditions: Huntington Disease
Register for Updates
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
NCT03587701
Recruiting
A Phase II randomized, placebo controlled study design of anakinra (Kineret) in corticosteroid-resistant or intolerant Meniere's disease (CR-MD)and corticosteroid-resistant or intolerant autoimmune inner ear disease (CR-AIED) patients. Patients will be randomized by a 2:1 allocation to anakinra or placebo for 42 continuous days. After day 42, a second placebo-controlled period will begin for an additional 42 days. This will be followed by a 264 day observation period, during which, hearing decli... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/19/2025
Locations: Northwell Health, Hearing& Speech Center, New Hyde Park, New York
Conditions: Autoimmune Inner Ear Disease, Meniere's Disease
Register for Updates
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
NCT04617522
Recruiting
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Pacific Shores Medical Group, Long Beach, California +9 locations
Conditions: Advanced or Metastatic Solid Tumor, Liver Failure
Register for Updates
CD4^LVFOXP3 in Participants With IPEX
NCT05241444
Recruiting
This first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of CD4\^LVFOXP3 in up to 30 evaluable human participants with IPEX and evaluate the impact of the CD4\^LVFOXP3 infusion on the disease.
Gender:
MALE
Ages:
Between 4 months and 35 years
Trial Updated:
05/19/2025
Locations: Lucile Packard Children's Hospital, Palo Alto, California
Conditions: IPEX
Register for Updates